Enveric Biosciences Announces Patent Issuance

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Positive)

Key Terms

neuroplastogenic medical

Neuroplastogenic describes a drug, molecule or treatment that actively promotes neuroplasticity — the brain’s ability to rewire itself by creating or strengthening connections between nerve cells. Think of it as encouraging a tangled garden path to be replanted and smoothed so signals travel more easily; for investors, neuroplastogenic activity can signal potential for lasting benefit in neurological or psychiatric disorders, larger market opportunity, and distinct regulatory and development risks.

12/29/2025 - 08:00 AM

U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” (the “‘179 patent”), with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders.

The ‘179 patent expands the protection of Enveric’s pipeline of potentially neuroplastogenic and non-hallucinogenic molecules and strengthens the Company’s ability to target neuropsychiatric, neurological, and addiction disorders for patients with few options. With the new molecules, Enveric may be able to target key receptors in new ways, resulting in drug candidates with efficacy and safety profiles that were not previously achievable. The expanded pipeline of patent protected molecules provides additional opportunity for licensing and partnerships with pharmaceutical companies making investments in the neuropsychiatric field.

In addition, for pharmaceutical corporations to justify the commitment to a comprehensive clinical development campaign, sufficiently strong intellectual property protection will be required to ensure return on investment is achievable. Strong intellectual property is therefore an important component of a drug candidate’s value proposition. Composition of matter protection, as realized in the ‘179 patent, is one of the stronger forms of intellectual property protection attainable for novel molecules.

The molecules covered by ‘179 patent are based on known compounds with relevant pharmacological activity. Like other Enveric novel molecules, these compounds are chemically altered to potentially improve efficacy and reduce side effects relative to the existing compounds. These novel molecules have the potential to outperform currently available pharmaceutical agents used for treatment of neuropsychiatric conditions.

“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “As our intellectual property footprint and portfolio of patented molecules expand, the impact of our efforts is crystalizing into a significant position within the overall industry, providing the Company with a compelling future to pursue.”

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT_2Aand 5-HT_1Breceptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; obtain licenses and partnerships with pharmaceutical companies; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.